Insecticides (India) Ltd FY26 Results

Insecticides (India) Ltd has announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a standalone revenue from operations of ₹2,144.14 crore, marking a 7.09% increase compared to ₹2,002.26 crore in the previous fiscal year. Consolidated revenue also saw a similar trend, rising by 7.00% to ₹2,140.01 crore.

Despite the revenue growth, standalone net profit for the fiscal year saw a marginal decline of 2.83%, standing at ₹135.82 crore, down from ₹139.77 crore in FY25. Consolidated net profit also decreased by 1.84% to ₹139.41 crore from ₹142.02 crore.

Reader Takeaway: Top-line growth continues, but margin pressures led to a slight profit dip; new ESPS scheme approved.

What just happened

Insecticides (India) Ltd announced its fiscal year 2026 audited financial results. Standalone revenue increased by 7.09% to ₹2,144.14 crore, while net profit decreased by 2.83% to ₹135.82 crore. Consolidated revenue grew 7.00% to ₹2,140.01 crore, with consolidated profit declining 1.84% to ₹139.41 crore.

The company also approved the 'IIL ESPS Scheme 2026' to issue up to 200,000 equity shares. Key personnel changes include the resignation of Mrs. Nikunj Aggarwal as Whole Time Director and the appointment of Mr. Sanskar Aggarwal as a Whole Time Director.

Why this matters

The consistent revenue growth indicates sustained demand for the company's products. However, the dip in profitability, even with higher sales, suggests potential pressure on margins or increased costs, which investors should monitor. The ESPS scheme could be an incentive for employees but might lead to minor equity dilution. Leadership changes can signal succession planning or shifts in strategic direction.

The backstory

Insecticides (India) Ltd is a significant player in the agrochemical sector, manufacturing and marketing a wide range of pesticides, herbicides, and fungicides. The company has a history of expanding its product portfolio and distribution network. This latest financial report reflects its performance in a competitive agricultural input market.

What changes now

With the financial year concluded and results announced, the focus shifts to the company's performance in the upcoming quarters. The approved ESPS scheme will likely be implemented, potentially leading to a slight increase in the number of outstanding shares. The new appointments in leadership roles will shape the company's operational and sales strategies moving forward.

Risks to watch

Potential margin pressures due to rising input costs or competitive pricing could impact future profitability. Any significant equity dilution from the ESPS scheme needs to be evaluated against its intended benefits. Changes in regulatory policies for agrochemicals or adverse weather conditions impacting agricultural output could also pose risks.

Peer comparison

(No peer comparison data available in the filing. Grounded search indicates key competitors in the Indian agrochemical space include UPL Ltd, Bayer CropScience, Rallis India, and PI Industries. These companies also focus on revenue growth and profitability, navigating similar market dynamics.)

Context metrics (time-bound)

Standalone Financials (FY26 vs FY25):

• Revenue from operations: ₹2,144.14 crore vs ₹2,002.26 crore (up 7.09%)
• Profit for the year: ₹135.82 crore vs ₹139.77 crore (down 2.83%)

Consolidated Financials (FY26 vs FY25):

• Revenue from operations: ₹2,140.01 crore vs ₹1,999.95 crore (up 7.00%)
• Profit for the year: ₹139.41 crore vs ₹142.02 crore (down 1.84%)

ESPS Scheme 2026: Up to 2,00,000 equity shares approved.

AGM Date: August 12, 2026.

What to track next

Investors will be watching for management commentary on the reasons for the profit decline despite revenue growth, and strategies to improve margins. The successful implementation and impact of the ESPS scheme, as well as the performance of the newly appointed Whole Time Director, will also be key points to track.